Literature DB >> 10488181

Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis.

J Maertens1, J Verhaegen, H Demuynck, P Brock, G Verhoef, P Vandenberghe, J Van Eldere, L Verbist, M Boogaerts.   

Abstract

Efforts to improve the diagnosis of invasive aspergillosis (IA) have been directed towards the detection of fungal antigens, including galactomannan (GM). However, previous evaluations of GM detection have been hampered by a lack of proven cases of IA and by a nonserial study design. This prospective study assessed the diagnostic value of serial screening for circulating GM by using a recently developed sandwich enzyme-linked immunosorbent assay (ELISA) for prolonged-neutropenic and/or steroid-treated patients with hematological disorders. Serum GM levels were monitored twice weekly for 186 consecutive patients at increased risk for IA. The patients were stratified according to the likelihood of IA (proven, probable, possible, and no evidence of IA) by using stringent criteria. Proven IA was defined by characteristic histopathological findings together with a positive culture for Aspergillus species. Autopsy and culture from autopsy specimens was used to verify both positive and negative test results. A total of 2,172 serum samples were tested from 243 episodes (mean, 9 samples/episode). Based on the analysis of 71 patients with confirmed disease status (culture and histology), the sensitivity and specificity of serial GM monitoring were 92.6 and 95.4%, respectively. The positive predictive value was almost 93%, the negative predictive value was 95%, and the efficacy was 94%. False-positive reactions occurred at a rate of nearly 8%, although this figure might have been overestimated. Less than 1% of all tested sera were considered inconclusive. In more than half of the cases, antigenemia was detected before clinical suspicion of IA (median, 6 days before). Serial determination of serum GM by the sandwich ELISA technique is a sensitive tool for the diagnosis of IA in hematological patients at risk. This approach may substantially influence clinical management with regard to preemptive and empirical antifungal therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488181      PMCID: PMC85532          DOI: 10.1128/JCM.37.10.3223-3228.1999

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

Review 1.  Statistical methods in microbiology.

Authors:  D M Ilstrup
Journal:  Clin Microbiol Rev       Date:  1990-07       Impact factor: 26.132

Review 2.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

Authors:  D W Denning; D A Stevens
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  Value of antigen detection in predicting invasive pulmonary aspergillosis.

Authors:  T R Rogers; K A Haynes; R A Barnes
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

4.  Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillus fumigatus antigen radioimmunoassay.

Authors:  G H Talbot; M H Weiner; S L Gerson; M Provencher; S Hurwitz
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

5.  New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test.

Authors:  R Kappe; A Schulze-Berge
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

6.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

Authors:  P Francis; J W Lee; A Hoffman; J Peter; A Francesconi; J Bacher; J Shelhamer; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

7.  Cyclophosphamide induces false-positive results in detection of aspergillus antigen in urine.

Authors:  K Hashiguchi; Y Niki; R Soejima
Journal:  Chest       Date:  1994-03       Impact factor: 9.410

8.  Detection of Aspergillus galactomannan antigen in foods and antibiotics.

Authors:  R Ansorg; R van den Boom; P M Rath
Journal:  Mycoses       Date:  1997-12       Impact factor: 4.377

9.  Rat monoclonal antibodies against Aspergillus galactomannan.

Authors:  D Stynen; J Sarfati; A Goris; M C Prévost; M Lesourd; H Kamphuis; V Darras; J P Latgé
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

10.  Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response.

Authors:  J Aisner; P H Wiernik; S C Schimpff
Journal:  Ann Intern Med       Date:  1977-05       Impact factor: 25.391

View more
  66 in total

Review 1.  The pulmonary physician in critical care 1: pulmonary investigations for acute respiratory failure.

Authors:  J Dakin; M Griffiths
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Pulmonary infiltrates in immunosuppressed patients: analysis of a diagnostic protocol.

Authors:  Cristina Danés; Julián González-Martín; Tomàs Pumarola; Ana Rañó; Natividad Benito; Antoni Torres; Asunción Moreno; Montserrat Rovira; Jorge Puig de la Bellacasa
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures.

Authors:  A Rañó; C Agustí; P Jimenez; J Angrill; N Benito; C Danés; J González; M Rovira; T Pumarola; A Moreno; A Torres
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

4.  Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis.

Authors:  Claudine Pinel; Hélène Fricker-Hidalgo; Bernadette Lebeau; Frédéric Garban; Rébecca Hamidfar; Pierre Ambroise-Thomas; Renée Grillot
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

5.  Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic cancer patients.

Authors:  Georg Maschmeyer
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

Review 6.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis.

Authors:  Laurence Millon; Renaud Piarroux; Eric Deconinck; Claude-Eric Bulabois; Frédéric Grenouillet; Pierre Rohrlich; Jean-Marc Costa; Stéphane Bretagne
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

8.  Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients.

Authors:  Birgit Spiess; Dieter Buchheidt; Corinna Baust; Heyko Skladny; Wolfgang Seifarth; Udo Zeilfelder; Christine Leib-Mösch; Handan Mörz; Rüdiger Hehlmann
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome.

Authors:  Emmanuel Roilides; Efterpi Pavlidou; Frantzis Papadopoulos; Christos Panteliadis; Evangelia Farmaki; Maria Tamiolaki; John Sotiriou
Journal:  Pediatr Nephrol       Date:  2003-03-18       Impact factor: 3.714

Review 10.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.